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GRAVES’ OPHTHALMOPATHY EVOLUTION STUDIED BY MRI DURING
CHILDHOOD AND ADOLESCENCE
FRANCO ANTONIAZZI, MD, GIORGIO ZAMBONI, MD, ROBERTO CERINI, MD, SILVANA LAURIOLA, MD,
ALBERTO DALL’AGNOLA, MD, AND LUCIANO TATO`, MD
Pediatric patients with Graves’ disease (n = 26) were studied longitudinally by magnetic resonance imaging of the orbits,
allowing an assessment of the enlargement of the extraocular muscles and orbital volume variations. The positive outcome of
Graves’ ophthalmopathy correlated with low TRAb (autoantibodies to thyroid-stimulating hormone receptor) titers at diagnosis
and during follow-up and with prepubertal condition at diagnosis. (J Pediatr 2004;144:527-31)
Graves’ ophthalmopathy (GO) is a complication of Graves’ disease characterized by proptosis, caused by the enlargement ofthe extraocular muscles and augmentation of orbital connective tissue and fat.1 As opposed to adults, children withGraves’ disease rarely have severe infiltrative ophthalmopathy, and exophthalmos is generally mild, nonprogressive, and
possibly reversible.2
The aim of the current study was to better understand the role of residual pubertal orbital growth in the evolution of GO.
To this purpose, we did a longitudinal study on a group of children and adolescents affected by Graves’ hyperthyroidism, using
magnetic resonance imaging (MRI) of the orbits.
METHODS
Consecutive Italian patients (n = 26, 21 girls) with Graves’ disease from the endocrine outpatients of our clinic took part in
the study. Informed consent was obtained from the parents of each patient before starting the study, and the local hospital ethics
committee approved the study.
At the time of diagnosis, the patients’ mean age was 10.15 ± 2.69 years (age range, 4.26-14.65 years); 13 were prepubertal,
and 13 showed Tanner stage $2.
The diagnosis of Graves’ disease was established by the detection of elevated serum-free T3 (FT3) and free T4 (FT4)
concentrations and suppressed thyroid-stimulating hormone (TSH) levels, with high serum titers of autoantibodies to TSH
receptor (TRAb), typical thyroidal echographic pattern, and high and diffuse 99Tc thyroidal uptake. A goiter was clinically evident
at diagnosis in 22 of the 26 patients.
An ophthalmic evaluation was done on all patients at diagnosis, including
measurements of proptosis with the use of the Hertel exophthalmometer. A value >20
mm was considered diagnostic of exophthalmus.1,3 We considered patients to be affected
by GO if they had clinical signs of ocular involvement (ie, upper lid retraction, lid lag, or
staring eyes) with exophthalmus or MRI signs of muscular enlargement.
MRI of the orbital region was performed shortly after the diagnosis of Graves’
disease (mean age, 10.49 ± 2.61 years; range, 4.71-14.81) to discover the presence of
alterations in the contents of the orbital tissues. MRI (1.5-T superconductive magnetic
unit; Somatom 58, Siemens, Erlangen, Germany) was done with SE T2-weighed
transversal scans (TR/TE, 2200/90 ms), using a 5-mm slice thickness, 1-mm distanct
factor, subsequently by SE T1-weighed axial and sagittal scans (TR/TE, 550/15 ms), using
a 3-mm slice thickness, 0.5-mm distanct factor, and finally by SE T1-weighed fat
suppression coronal scan (TR/TE, 650/15 ms). In particular, we evaluated bony orbital
volume,4,5 muscular enlargement,6 muscular fat infiltration, and increase in orbital fat.
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Table. Age, pubertal stage, opthalmologic signs, intraorbital volume, MRI pattern, TRAb levels both at
diagnosis (I) and at the end of follow-up (II), and clinical outcome of patients studied
Age at MRI (y)
Pubertal stage
(Tanner) Proptosisa (mm) Orbital volume (cm3)b
Patient I II I II I R I L II R II L I R I L II R II L
1 10.5 14.3 Ph2, B2 Ph4, B4 23 21 20 19 24.5 24.4 25.6 25.6
2 6.5 8.6 Ph1, G1 Ph1, G1 22 23 20 20 24.3 24.4 25.3 25.2
10 8.2 16.7 Ph1, B1 Ph5, B5 24 23 20 19 24.3 24.2 25.5 25.5
14 9.9 17.4 Ph1, B1 Ph4, B4 20 22 18 18 24.5 24.7 26.0 26.1
15 6.2 10.7 Ph1, B1 Ph2, B2 20 20 18 18 25.0 25.1 26.0 25.9
24 10.5 14.6 Ph1, B1 Ph4, B4 23 22 20 20 23.0 23.0 24.2 24.1
Group A
(n = 6)
8.7 ± 1.9 13.7 ± 3.4 5 Prepub
1 Pub
1 Prepub
5 Pub
22.0 ± 1.7e 21.8 ± 1.2e 19.3 ± 1.0 19.0 ± 0.9 24.2 ± 0.7 24.3 ± 0.7 25.5 ± 0.7 25.4 ± 0.7
6 12.5 14.7 Ph3, B3 Ph4, B4 20 19 24 23 27.0 26.8 27.4 27.3
8 13.8 21.3 Ph3, B3 Ph5, B5 20 22 20 21 26.5 26.5 27.0 27.0
17 14.3 17.4 Ph4, B4 Ph5, B4 19 19 22 23 26.5 26.5 26.9 27.0
21 11.8 15.3 Ph2, B2 Ph4, B4 22 22 21 20 28.0 28.0 29.1 29.0
26 14.8 19.2 Ph3, G3 Ph5, G5 22 21 21 20 27.8 27.8 28.1 28.2
Group B
(n = 5)
13.4 ± 1.2 17.6 ± 2.7 5 Pub 5 Pub 20.6 ± 1.3h 20.6 ± 1.5h 21.6 ± 1.5i 21.4 ± 1.5i 27.2 ± 0.7 27.1 ± 0.7 27.7 ± 0.9 27.7 ± 0.9
3 13.6 21.0 Ph3, B3 Ph5, B5 19 19 19 18 25.9 25.8 26.4 26.4
4 4.7 6.9 Ph1, B1 Ph1, B1 17 18 18 18 22.1 22.2 22.7 22.8
5 13.2 15.2 Ph3, B3 Ph4, B5 20 20 19 20 26.8 26.8 27.2 27.3
7 11.5 13.5 Ph2, B2 Ph3, B3 18 18 19 18 24.5 24.5 24.9 24.8
9 10.9 14.6 Ph2, B2 Ph4, B4 18 18 18 18 23.0 23.1 23.8 23.8
11 10.5 13.0 Ph1, B1 Ph2, B3 19 20 19 20 24.7 24.8 25.2 25.3
12 10.1 20.2 Ph1, G1 Ph5, G5 20 20 20 19 25.0 25.0 26.5 26.5
13 13.6 20.2 Ph3, B3 Ph5, B5 18 18 19 18 27.1 27.1 27.6 27.7
16 8.8 12.9 Ph1, G1 Ph2, G2 18 17 18 17 26.0 26.0 27.1 27.1
18 7.5 12.5 Ph1, B1 Ph2, B3 17 17 18 18 24.7 24.7 25.7 25.8
19 11.3 17.6 Ph2, B3 Ph5, B5 20 19 19 18 27.0 26.9 27.7 27.6
20 8.8 14.7 Ph1, B1 Ph3, B4 17 17 19 18 22.0 22.0 23.0 23.0
22 12.7 17.2 Ph2, G2 Ph4, G4 20 20 19 19 28.5 28.5 29.6 29.7
23 7.8 13.8 Ph1, B1 Ph3, B3 19 18 20 20 24.2 24.1 25.5 25.6
25 8.4 15.3 Ph1, B1 Ph3, B4 18 19 19 19 26.0 26.2 27.2 27.3
Group C
(n = 15)
10.2 ± 2.7 15.2 ± 4.0 8 Prepub
7 Pub
1 Prepub
14 Pub
18.5 ± 1.1 18.5 ± 1.1 18.8 ± 0.7 18.5 ± 0.9 25.2 ± 2.0 25.3 ± 1,9 26.0 ± 2.1 26.1 ± 2.0
Group A, Patients with ophthalmopathy improvement or regression; group B, patients with ophthalmopathy persistence or worsening; group C, patients
without GO. Data are expressed as mean ± SD or median and range (min-max).
aSeparate value of right (R) and left (L) eyes (in mm) measured by Hertel exophtalmometer.
bSeparate value of right (R) and left (L) orbital volume (in cm3).
cTRAb U/I (normal values <15 U/I) values are expressed as median and range (min-max).
dOutcome of thyroid disease: MT, medical therapy; S, surgery: near-total thyroidectomy; CR, complete remission.
eP < .0001 vs group C.
fP < .05 vs group C and (P < .001) vs group B.
gP < .05 vs group C.
hP < .01 vs group C.
iP < .001 vs group C.
jP < .001 vs group C.
kP < .01 vs group C and (P < .05) vs group A.
Red, reduced; Prepub, prepubertal; Pub, pubertal.In our experience, normal values for orbital volume
(cm3) are as follows: female subjects: 22.6 ± 3.1 (5-10 years),
25.5 ± 2.8 (11-15 years), and 26.1 ± 2.5 (16-20 years); male
subjects: 23.8 ± 3.3 (5-11 years), 26.3 ± 2.7 (12-16 years), and
27.2 ± 1.8 (17-21 years). Patient data referred to this
population, and the values were expressed also as SD score
(measured value minus mean)/standard deviation.528 Antoniazzi et alThe medial and lateral rectus muscles were measured on
axial scans; the superior rectus and the levator palpebra
superior muscles were measured together as a single superior
muscle group; diameters of the superior muscle group, the
inferior rectus muscle, and the superior oblique muscle were
measured on coronal scans.7 The diameter of each muscle was
measured at its maximum. Extraorbital muscles were consid-The Journal of Pediatrics  April 2004
Table. continued
Obital volume (SDs) Muscular enlargement at MRI TRAb U/Ic
% D Orbital Volume I II I II I II Outcomed
4.5 0.6 0.1 + + (red) 185 55 S
4.0 0.2 0.4 + Almost  102 32 MT
6.0 0.5 0.2 + (right ++) Almost  405 120 CR
6.0 0.6 0.1 + + (red) 73 18 CR
4.0 0.8 1.1 +  21 20 MT
5.0 0.1 0.5 + + (red) 160 85 MT
4.9 ± 0.9f 0.4 ± 0.3 0.2 ± 0.5 131 (21-405)g 26 (12-85)
1.5 0.5 0.7

+ 400 258 S
2.0 0.4 0.4 + + 82 12 CR
1.5 0.4 0.3  + 280 256 S
3.5 0.9 1.3 + + 260 188 S
1.2 0.6 0.5 + + 102 10 CR
1.9 ± 0.9 0.5 ± 0.2 0.6 ± 0.4 260 (82-400)j 188 (10-258)k
2.0 0.1 0.1   33 25 S
2.5 0.2 0.0   41 38 MT
1.5 0.5 0.6   27 32 MT
1.5 0.4 0.2   110 54 MT
3.5 0.1 0.6   55 48 S
2.0 0.7 0.1   68 24 MT
6.0 0.4 0.4   31 45 S
2.0 0.6 0.6   28 22 CR
4.0 0.7 0.3   110 87 MT
4.0 0.7 0.1   55 18 MT
2.5 0.5 0.6   38 10 CR
4.5 0.2 0.9   98 16 CR
4.0 0.8 1.4   68 25 CR
5.5 0.5 0.0   45 18 CR
4.5 1.1 0.6   68 75 S
3.3 ± 1.5 0.4 ± 0.4 0.2 ± 0.6 55 (27-110) 25 (10-87)ered enlarged when diameters were $+2 SD of our personal
data; specifically, medial rectus $4.7 mm, lateral rectus $4.6
mm, superior group $5.3 mm, inferior rectus $5.8 mm, and
superior oblique $4.0 mm.
A second MRI was performed with the the same
MRI apparatus and identical measures used, after a mean
period of 4.86 ± 2.28 years (range, 2.02-10.13) and atGraves’ Ophthalmopathy Evolution Studied By MRI During Childhood and
Adolescencea mean age of 15.35 ± 3.54 years (range, 6.91-21.27).
At this stage, each patient was euthyroid: 9 were in
complete remission, 8 were receiving L-thyroxine replace-
ment treatment after near total thyroidectomy, and 9 were
receiving combined treatment with L-thyroxine and pro-
pylthiouracil. All patients and their parents were non-
smokers.529
Serum titers of anti-TRAb were measured by ra-
dioreceptor assay (TRAK-Assay, BRAHMS Diagnostica
GmbH, Berlin, Germany), with the use of the TSH receptor
isolated from porcine thyroid; the intra-assay and interassay
coefficients of variation were < 7.2% and < 13.2%, re-
spectively. The analytical sensitivity of this assay was 2.4 U/L.
Results are expressed as mean ± SD and as median and
range. Statistical analysis was performed with the use of the
unpaired Student t test, with the Bonferroni correction when
appropriate and v2 analysis and Mann-Whitney nonparamet-
ric test in the case of abnormal distribution. All statistical
analyses were performed with the use of a data analysis system
(StatView 4.5, Abacus Concepts, Inc, Berkeley, Calif) run on
an Apple PowerMac computer. Statistical significance was set
at a value of P < .05.
RESULTS
The Table shows age, pubertal stage, ophthalmologic
signs, intraorbital volume, MRI pattern, and TRAb levels of
the patients studied, both at diagnosis and at the end of
follow-up. Values of calculated intraorbital volume are
reported as absolute numbers (cm3) and in SD scores
compared with the normal data referring to the same age
group. Muscular swelling is reported as present (+) or absent if
the dimensions of extraocular muscles were or were not greater
than the normal limit for our population.
Clinical signs of GO and exophthalmos were evident at
the time of diagnosis in 8 of 26 patients. The remaining
patients showed no symptoms or signs of ocular involvement
at this time. MRI confirmed exophthalmos, when it was
clinically present, by a pattern of muscular enlargement, with
no muscular fat infiltration or increase in intraorbital adipose
tissue. Another patient (No. 15) showed a pattern of muscular
enlargement despite the absence of clinical signs of GO. MRI
of the orbital region was negative in all the other patients.
During follow-up, another 2 patients (Nos. 6 and 17),
both pubertal at diagnosis and in a euthyroid state, showed
clinical and MRI patterns of GO 15 and 22 months from
diagnosis, respectively. They had had no clinical or MRI signs
of GO at diagnosis, although high titers of TRAb were
evident at diagnosis and during follow-up.
During follow-up, the patients who had had ocular
involvement at diagnosis had almost complete regression of
clinical signs and symptoms of GO. The MRI pattern of
muscular enlargement showed no variation in 3 patients (Nos.
8, 21, and 26) who were pubertal at diagnosis; discrete
regression in 3 patients (Nos. 1, 14, and 24): 2 prepubertal and
1 pubertal at diagnosis; and almost complete regression in 3
patients (Nos. 2, 10, and 15) who were prepubertal at
diagnosis.
The increase in orbital volume between the first and
second MRI was 3.5% ± 1.5%, but it was more significant in
prepubertal rather than in pubertal patients (4.46% ± 1.60% vs
2.50% ± 1.18%; P < .01).
Hyperthyroid patients with GO at diagnosis and during
follow-up had significantly higher anti-TRAb titers than those530 Antoniazzi et alwithout GO (mean ± SD: 188.2 ± 131.7 vs 58.3 ± 28.5 U/L;
P < .05; median (range, minimum to maximum): 160 (21 to
405) vs 55 (27 to 110) U/L). The 95% upper-level confidence
interval between groups was 201.7 U/L, so we took this value
as a cutoff for higher risk of GO. There were no significant
differences in other measures studied (age at diagnosis, orbital
volume, FT3, FT4, TSH, anti-thyroglobulin antibody, and
anti-thyroid peroxidase antibody levels, data not shown)
among groups matched for sex, pubertal stage, and therapeutic
options during follow-up.
We subdivided all the patients showing clinical or MRI
signs of GO at diagnosis and during follow-up (11 total) into
2 groups, based on the evolution of GO: 6 patients had an
improvement or regression of ophthalmopathy (group A),
whereas 5 showed persistence or worsening of the ophthal-
mopathy (group B).
The Table shows these 2 groups of patients compared
with hyperthyroid patients without GO (group C). At
diagnosis, 5 of the 6 patients in group A were prepubertal,
whereas all 5 patients in group B were pubertal; the difference
was statistically significant by v2 analysis (P < .01). The
patients in group A had an increase in orbital volume that was
significantly higher than that of the children in group B
(4.91% ± 0.91% vs 1.94% ± 0.92%; P < .001) and statistically
different from that of group C.
TRAb levels of the patients in group B were significantly
higher at the end of follow-up than both those of the patients
in group A (P < .05) and group C (P < .01).
DISCUSSION
Graves’ ophthalmopathy is less common in children
than in adults. Orbital signs and symptoms occur in
approximately one half of hyperthyroid children, and exoph-
thalmos, when present, is usually mild.2 The cause of this
different behavior of GO in hyperthyroid children and adults
is not clearly understood.
Because our patients with GO had significantly higher
TRAb titers than those without ophthalmopathy, elevated
TRAb titers at diagnosis6 and especially during follow-up
were associated with an elevated risk of persisting GO or its
onset during follow-up. In particular, patients with TRAb
levels >200 U/L have an increased risk for GO. On the
contrary, the patients with better progression of GO had low
TRAb titers.
In our pediatric patients with GO, MRI showed only
the enlargement of the extraocular muscles. This finding is
typical of the active, edematous stage of the eye disease in
children and adolescents, in which the fibrotic stage is
uncommon. Moreover, MRI confirmed regression of the
ophthalmopathy in the 6 patients in group A, already clinically
evidenced.
During follow-up, the prepubertal patients who had
a tendency to GO regression also showed an increse of orbital
volume. Probably during pubertal development, the residual
orbital growth could create a physiologic decompression with
a positive effect on the evolution of GO.The Journal of Pediatrics  April 2004
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